Axitinib-13C-d3 (Synonyms: AG-013736-13C-d3) |
Catalog No.GC46899 |
악시티닙-13C-d3(AG-013736 13CD3)은 13C 표지 및 중수소 표지 악시티닙입니다. 악시티닙은 VEGFR1, VEGFR2, VEGFR3 및 PDGFRβ에 대해 IC50이 각각 0.1, 0.2, 0.1-0.3, 1.6 nM인 다중 표적 티로신 키나제 억제제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1261432-00-1
Sample solution is provided at 25 µL, 10mM.
Axitinib-13C-d3 is intended for use as an internal standard for the quantification of axitinib by GC- or LC-MS. Axitinib is a VEGFR inhibitor (IC50s = 1.2, 0.25, and 0.29 nM for VEGFR1, -2, and -3, respectively).1 It also inhibits c-Kit and PDGFRβ (IC50s = 1.7 and 1.6 nM, respectively). It inhibits VEGF-induced migration of and tube formation by human umbilical vein endothelial cells (HUVECs).2 Axitinib (1-100 mg/kg) reduces microvessel density, a marker of angiogenesis, and tumor growth in MV522 colon carcinoma, A375 melanoma, SN12C-GFP renal carcinoma, and U87 glioma mouse xenograft models in a dose-dependent manner. Formulations containing axitinib have been used in the treatment of renal cell carcinoma.
1.Giles, F.J., Bellamy, W.T., Estrov, Z., et al.The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)Leuk. Res.30(7)801-811(2006) 2.Hu-Lowe, D.D., Zou, H.Y., Grazzini, M.L., et al.Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3Clin. Cancer Res.14(22)7272-7283(2008)
Average Rating: 5
(Based on Reviews and 1 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *